
Opinion|Videos|June 5, 2024
Evolving Commercialization and Distribution Models for PDTs
The panel discusses the challenges of delivering prescription digital therapeutics (PDTs) to patients, challenges caused by PDTs being considered behavioral health benefits, pharmacy benefits, medical benefits, and durable medical equipment benefits.
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Five Ways AI Is Transforming Cancer Care—and Companies That Are Making It Happen
2
Cefdinir Nearly Doubles Outpatient Uncomplicated UTI Treatment Failure Compared With Cephalexin
3
Intermountain Spans Time Zones, Cultures to Bring Oncology Care to Alaska
4
NIH F32 Grants Boost Early-Career Researchers’ Success
5















































